share_log

Chimerix | 8-K: Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

SEC ·  Mar 21 10:06

Summary by Moomoo AI

Chimerix reported a Q4 2024 net loss of $23.0 million ($0.25 per share), compared to $18.2 million loss in Q4 2023. Revenue was minimal at $57,000, while R&D expenses increased to $17.7 million and G&A expenses rose to $7.0 million. The company ended 2024 with $140.1 million in available capital and no debt.For full-year 2024, Chimerix posted a net loss of $88.4 million ($0.99 per share) versus $82.1 million loss in 2023. The company's NDA for Dordaviprone, targeting H3 K27M-mutant diffuse glioma, is under FDA review with a PDUFA date of August 18, 2025.Jazz Pharmaceuticals has agreed to acquire Chimerix for $8.55 per share in cash, totaling approximately $935 million. The transaction is expected to close in Q2 2025, subject to customary conditions including tender of majority shares.
Chimerix reported a Q4 2024 net loss of $23.0 million ($0.25 per share), compared to $18.2 million loss in Q4 2023. Revenue was minimal at $57,000, while R&D expenses increased to $17.7 million and G&A expenses rose to $7.0 million. The company ended 2024 with $140.1 million in available capital and no debt.For full-year 2024, Chimerix posted a net loss of $88.4 million ($0.99 per share) versus $82.1 million loss in 2023. The company's NDA for Dordaviprone, targeting H3 K27M-mutant diffuse glioma, is under FDA review with a PDUFA date of August 18, 2025.Jazz Pharmaceuticals has agreed to acquire Chimerix for $8.55 per share in cash, totaling approximately $935 million. The transaction is expected to close in Q2 2025, subject to customary conditions including tender of majority shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 279

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
Ocean Biomedical
OCEA
0.127
OSR Holdings
OSRH
3.528
Alumis
ALMS
5.100
Theratechnologies
THTX
1.8498
Molecular
MOLN
4.600
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Fed rate cut expectations for 2025 intensify. What’s your market outlook?
44%
56%
Bullish
Bearlish
1577 votes
FOMC Press Conference, March 19, 2025